Aegle Therapeutics

Aegle Therapeutics Corp. is a clinical-stage biotechnology company based in Arlington, Massachusetts. The company currently employs five people and generates approximately $2.5 million in annual revenue. Aegle Therapeutics focuses on developing innovative extracellular vesicle (EV) therapies to address rare and serious diseases with limited treatment options. Aegle’s proprietary platform technology isolates native EVs from stem cells. These EVs contain a complex mix of proteins and nucleic acids that can influence recipient cells in various ways, promoting regenerative healing, reducing inflammation, and modulating the immune system. This approach allows Aegle to develop potential treatments for a wide range of conditions across diverse therapeutic areas such as dermatology, immunology-based diseases, and protein deficient disorders. Aegle Therapeutics differentiates itself through its unique EV isolation technology and its focus on developing therapies for diseases with significant unmet medical needs. Their innovative approach holds the potential to revolutionize treatment options for patients suffering from rare and serious conditions. To learn more about Aegle Therapeutics and their groundbreaking research, visit their website at www.aegletherapeutics.com.